ClinicalTrials.gg
CompletedNCT01455701Updated Nov 4, 2019

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

A Phase 1 interventional study of Tocilizumab in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 20 sites in 8 countries. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2019-11-04.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2016, 10 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
Up to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
16th of 21
11 · median 52
Started
2012
with 3 others
Phase 1
4 of 21
none open now
Registered
8th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 16th largest by enrollment, is one of 4 that started in 2012, is one of 4 in phase 1, and was the 8th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: Up to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

This is a multi-center, open-label single-arm study to investigate the pharmacokinetics and safety of tocilizumab (RoActemra/Actemra) in participants less than 2 years old with active sJIA. Participants will receive tocilizumab infusions every 2 weeks. The anticipated time on study treatment is 12 weeks (Main evaluation period). Participants will have the option to continue tocilizumab treatment until participant reaches 2 years of age or up to one year from baseline, whichever is longer. An optional extension period will follow the main evaluation period.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfils international league of associations for rheumatology (ILAR) classification criteria for sJIA
  • Duration of sJIA symptoms lasting for at least 1 months subsequent to diagnosis of sJIA
  • Presence of active disease as determined by the presence of:

    1. Greater than or equal to (>=) 2 active joints at screening and baseline, with at least 14 consecutive days of temperature recordings, which may include the presence or absence of fever (>=38 degree Celsius) during the time between screening and baseline; or
    2. >=2 active joints at screening and baseline, with a fever >=38 degree Celsius for at least 5 consecutive days during the time between screening and baseline; under these circumstances a participant does not need to complete a full 14 days of temperature diary entries to meet this inclusion criteria
  • Not currently receiving (CS) or if taking oral CS like prednisone or equivalent, the dose should be less than or equal to (\<=) 1 milligram per kilogram per day (mg/kg/day) and the dose has remained stable for at least 2 weeks prior to baseline
  • Not currently receiving methotrexate (MTX) or if taking MTX (together with either folic acid or folinic acid according to local standard-of-care), the dose has remained stable or has been discontinued for at least 4 weeks prior to baseline
  • Not currently receiving non-steroidal anti-inflammatory drugs (NSAIDs) or if taking NSAID, the dose has remained stable or has been discontinued for at least 2 weeks prior to baseline
  • If the participants has received previous treatment with any of the following biologic agents, these must have been discontinued according to the following timelines prior to the baseline visit and are not permitted during the study:

    1. Etanercept must have been discontinued within >= 2 weeks prior to baseline
    2. Anakinra must have been discontinued within >= 4 days prior to baseline
    3. Abatacept must have been discontinued within >= 12 weeks prior to baseline
    4. Infliximab or adalimumab must have been discontinued within >= 8 weeks prior to baseline
    5. Canakinumab must have been discontinued within >= 20 weeks prior to baseline
    6. Rilonacept must have been discontinued within >= 6 weeks prior to baseline
    7. Golimumab must have been discontinued within >= 10 weeks prior to baseline
    8. Certrolizumab pegol must have been discontinued within >= 10 weeks prior to baseline
  • History of inadequate clinical response (in the opinion of the treating physician) to NSAIDs and CS

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria:

  • Any , rheumatic disease or overlap syndrome other than sJIA
  • Not fully recovered from recent surgery or less than 6 weeks since surgery, at the time of screening visit; or planned surgery during the study (except for myringotomy surgery, which is permitted)

General Safety Exclusion Criteria:

  • Any significant concurrent medical or surgical condition which would jeopardize the participant's safety or ability to complete the trial
  • History of significant allergic or infusion reactions to prior biologic therapy or to any of the listed in tocilizumab product labelling documents
  • Inborn conditions characterized by a compromised immune system
  • Known (HIV) infection or other acquired forms of immune compromise
  • Evidence of serious uncontrolled concomitant diseases including but not limited to the nervous system, renal, hepatic or endocrine systems
  • Asthma for which the participant has required the use of oral or parenteral for >=2 weeks within 6 months prior to baseline visit
  • Any active acute, subacute, chronic or recurrent bacterial, viral or systemic fungal infection
  • History of atypical tuberculosis (TB)
  • Active TB requiring treatment at any point prior to screening visit
  • Positive TB test result at screen, unless treated with anti-TB therapy for at least 4 weeks prior to receiving study medication and chest radiograph is negative for active TB within 6 months of screening visit consistent with local practice
  • Any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completing within 4 weeks of the screening visit or oral antibiotics completing within 2 weeks of the screening visit
  • History of reactivation or new onset of a systemic infection such as herpes zoster or Epstein Barr virus within 2 months of the screening visit
  • History of or infection
  • Chronic hepatitis - viral or autoimmune
  • Significant cardiac or pulmonary disease
  • History or concurrent serious gastrointestinal disorders such as ulcer or inflammatory bowel disease, ulcerative colitis or other symptomatic lower gastrointestinal conditions, including ulcer and perforation
  • History of or current cancer or lymphoma
  • History of macrophage activation syndrome (MAS) within 3 months prior to the screening visit
  • Uncontrolled diabetes mellitus with elevated (HbA1c) as defined by age-specific standards

Excluded Previous or Concomitant Therapy:

  • Participation in another interventional clinical trial within the past 30 days or 5 serum half-lives of the investigative medication, whichever is longer
  • Previous treatment with tocilizumab
  • Administration of IV immunoglobulin within 4 weeks prior to the baseline visit
  • Previous treatment with any cell depleting therapies, including agents
  • Prior stem cell transplant at any time
  • Live or attenuated vaccines within 4 weeks prior to the baseline visit, or intending to receive while on study medication or 8 weeks following the last dose of study medication
  • Serum creatinine >1.5 (upper limit of normal for age and sex)
  • or ALT > 1.5 ULN (upper limit of normal for age and sex)
  • Total > 1.3 mg/dL (> 23 umol/L)
  • count \< 200 x103/μL (\< 200,000/mm3)
  • \< 7.0 g/dL (\< 4.3 mmol/L)
  • WBC count \< 6,200/mm3 (\< 6.2 x 109/L)
  • \< 2,500/ mm3 (\< 2.5x 109/L)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.

    Drug: Tocilizumab

Interventions

  • Tocilizumab will be administered as indicated in the arm description.

    Also known as: RoActemra, Actemra, RO4877533

06

What researchers measure

Primary outcomes

  1. Maximum Serum Concentration (Cmax) of Tocilizumab

    Pharmacokinetic profile of tocilizumab is evaluated in terms of model predicted Cmax at steady state. Pharmacokinetic-evaluable population includes all participants who provided at least one serum pharmacokinetic sample with valid concentration data.

    Time frame: Pre-infusion (Hour 0) on Days 1, 15, 29, 43, 57, 71, and 85; at the end of infusion on Days 1, 29 and 71; and anytime on Days 8, 36, and 78 (infusion length = 1 hour)

  2. Minimum Serum Concentration (Cmin) of Tocilizumab

    Pharmacokinetic profile of tocilizumab is evaluated in terms of observed Cmin at day 85. Pharmacokinetic-evaluable population.

    Time frame: Pre-infusion (Hour 0) on Days 1, 15, 29, 43, 57, 71, and 85; at the end of infusion on Days 1, 29 and 71; and anytime on Days 8, 36, and 78 (infusion length = 1 hour)

  3. Model predicted Area Under the Serum Concentration-Time Curve from Time Zero to End of Dosing (AUCtau) of Tocilizumab

    AUCtau is the model-predicted area under the tocilizumab serum concentration versus time curve from time zero to the end of dosing interval (2 weeks). Pharmacokinetic-evaluable population.

    Time frame: Pre-infusion (Hour 0) on Days 1, 15, 29, 43, 57, 71, and 85; at the end of infusion on Days 1, 29 and 71; and anytime on Days 8, 36, and 78 (infusion length = 1 hour)

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious AEs

    Time frame: Baseline up to end of the study (up to approximately 60 weeks)

07

Study locations

20 sites
  • Children's National Medical Center; Pediatric Rheumatology
    Washington, District of Columbia 20010-2970, United States
  • The University of Chicago;Department of Pediatrics
    Chicago, Illinois 60649, United States
  • University of Louisville Research Foundation, Inc; Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • The Floating Hospital for Children at Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Children's Hospital Boston Pediatric Medicine
    Boston, Massachusetts 02115, United States
  • Children's Speciality Center of Nevada
    Las Vegas, Nevada 89109, United States
  • Hackensack University Medical Center; Pediatric Rheumatology
    Hackensack, New Jersey 07601, United States
  • Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
    Cincinnati, Ohio 45229-3039, United States
  • Children's Hospital Of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Hospital Gral de Niños Pedro Elizalde
    Buenos Aires, 1270, Argentina
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Alberta Children'S Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Hospital For Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • McGill University; Montreal Children's Hospital; Inflammatory, Autoimmune & Bone
    Montreal, Quebec H4A 3J1, Canada
  • Klinik Bremen-Mitte; Prof. Hess-Kinderklinik
    Bremen, 28177, Germany
  • Semmelweis University; 2nd Department of Paediatrics
    Budapest, 1094, Hungary
  • Uniwersytecki Szpital Kliniczny Nr 4 im. M. Konopnickiej; Oddz. Kardiolog. i Reumatolog. dla Dzieci
    Lodz, 91-738, Poland
  • Uniwersytecki Szpital Dzieciecy w Lublinie; Oddzial Pediatrii, Chorob Pluc i Reumatologii
    Lublin, 20-093, Poland
  • Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica
    Valencia, 46026, Spain
08

References and documents

Publications

  • Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J. 2019 Aug 22;17(1):57. doi: 10.1186/s12969-019-0364-z. PubMed 31438986 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in Jul 2016, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2011
First posted
Oct 20, 2011
StartActual
Oct 26, 2012
Primary completionActual
Jul 28, 2016
CompletionActual
Jul 13, 2017
Last update
Nov 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01455701
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 20, 2011
Start date
Oct 26, 2012
Primary completion
Jul 28, 2016
Completion
Jul 13, 2017
Last update
Nov 4, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion